Exact Sciences Corporation
EXAS
주식 순위
#1153
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
주가
$104.91
마지막 동기화: 2026-03-23
시가총액
$20.03B
변동 (1일)
0.00%
변동 (1년)
67.24%
국가
US
거래 Exact Sciences Corporation (EXAS)
카테고리
Healthcare
Exact Sciences Corporation (EXAS)의 발행 주식 수
December 2025 기준 발행 주식 수: 189.74M
Exact Sciences Corporation의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 189.74M입니다. December 2024 말 기준 회사는 184.20M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Exact Sciences Corporation (EXAS)의 발행 주식 수 기록 (2000 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 189.74M | 0.56% |
| 2025 | 188.69M | 2.44% |
| 2024 | 184.20M | 2.25% |
| 2023 | 180.14M | 2.15% |
| 2022 | 176.35M | 2.92% |
| 2021 | 171.35M | 13.37% |
| 2020 | 151.14M | 15.15% |
| 2019 | 131.26M | 7.41% |
| 2018 | 122.21M | 5.64% |
| 2017 | 115.68M | 13.04% |
| 2016 | 102.34M | 11.07% |
| 2015 | 92.14M | 14.84% |
| 2014 | 80.23M | 18.87% |
| 2013 | 67.49M | 13.47% |
| 2012 | 59.48M | 13.27% |
| 2011 | 52.51M | 29.80% |
| 2010 | 40.46M | 23.37% |
| 2009 | 32.79M | 20.50% |
| 2008 | 27.21M | 0.99% |
| 2007 | 26.95M | 1.64% |
| 2006 | 26.51M | 0.91% |
| 2005 | 26.27M | 3.69% |
| 2004 | 25.33M | 33.96% |
| 2003 | 18.91M | 2.59% |
| 2002 | 18.43M | 11.80% |
| 2001 | 16.49M | 1,027.91% |
| 2000 | 1.46M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 371.00M | 95.53% |
US
|
|
| 705.30M | 271.72% |
US
|
|
| 143.28M | -24.49% |
US
|
|
| - | - |
CN
|
|
| 282.00M | 48.63% |
US
|
